DDO-4033

• Description :

  DDO-4033 is a SPOP inhibitor (IC50 = 16.9 μM, Kd = 15.1 μM) . DDO-4033 impairs the malignant migration, invasion, and proliferation of clear cell renal cell carcinoma (ccRCC) cell lines. DDO-4033 disrupts SPOP recruitment to its substrate LATS1, inhibits its polyubiquitination and subsequent degradation, and upregulates LATS1 expression. DDO-4033 has promising antitumor activity and is promising for renal cell carcinoma research[1].

• UNSPSC :

  12352005

• Target :

  E1/E2/E3 Enzyme; YAP

• Related Pathways :

  Metabolic Enzyme/Protease; Stem Cell/Wnt

• Field of Research :

  Cancer

• Smiles :

  C#CC1=C([N+]([O-])=O)C=C(C(NC2=CC(C)=NN2C(N3)=NC(CCC)=CC3=O)=O)C=C1

• Molecular Formula :

  C20H18N6O4

• Molecular Weight :

  406.39

• References & Citations :

  [1]Zhang Q, et al. Discovery of 2-Pyrazolylpyrimidinone Derivatives as New SPOP Inhibitors for Renal Cell Carcinoma Therapy. J Med Chem. 2025 Jul 24;68 (14) :14945-14961.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported